U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H23NO7P2
Molecular Weight 319.2289
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBANDRONIC ACID

SMILES

CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

HIDE SMILES / InChI
Molecular Formula C9H23NO7P2
Molecular Weight 319.2289
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:57:11 UTC 2023
Edited
by admin
on Sat Dec 16 15:57:11 UTC 2023
Record UNII
UMD7G2653W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBANDRONIC ACID
EMA EPAR   INN   MART.   MI   WHO-DD  
INN  
Official Name English
IBANDRONATE [VANDF]
Common Name English
IBANDRONIC ACID ACCORD
Brand Name English
NSC-722623
Code English
Ibandronic acid [WHO-DD]
Common Name English
IBANDRONIC ACID [EMA EPAR]
Common Name English
IBANDRONIC ACID [MART.]
Common Name English
IASIBON
Brand Name English
IBANDRONATE
VANDF  
Common Name English
BONDENZA
Brand Name English
(1-HYDROXY-3-(METHYLPENTYLAMINO)PROPYLIDENE)DIPHOSPHONIC ACID
Systematic Name English
IBANDRONIC ACID [MI]
Common Name English
IBANDRONIC ACID SANDOZ
Brand Name English
ibandronic acid [INN]
Common Name English
IBANDRONIC ACID TEVA
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BONDRONAT (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
NCI_THESAURUS C67439
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS BONDENZA (WITHDRAWN: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
NCI_THESAURUS C443
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IASIBON (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS HALAVEN (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID SANDOZ (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID ACCORD (AUTHORIZED: WOUNDS AND INJURIES)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
NDF-RT N0000007707
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
WHO-VATC QM05BA06
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS BONVIVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID ACCORD (AUTHORIZED: NEOPLASTIC PROCESSES)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS DESTARA (WITHDRAWN: CANCER, HYPERCALCIMA)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID SANDOZ (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
WHO-ATC M05BA06
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
LIVERTOX 494
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IBANDRONIC ACID TEVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS IASIBON (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS XGEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
NDF-RT N0000175579
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
EMA ASSESSMENT REPORTS BONDRONAT (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL997
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
EPA CompTox
DTXSID5048340
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
MERCK INDEX
m6182
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY Merck Index
FDA UNII
UMD7G2653W
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
RXCUI
115264
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
ALTERNATIVE
IUPHAR
3059
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
NCI_THESAURUS
C65874
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
MESH
C073007
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
DRUG CENTRAL
1404
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
WIKIPEDIA
IBANDRONIC ACID
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
NSC
722623
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
SMS_ID
100000085439
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
EVMPD
SUB08092MIG
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
RXCUI
115265
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
DRUG BANK
DB00710
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
PUBCHEM
60852
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
INN
7189
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
DAILYMED
UMD7G2653W
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
CAS
114084-78-5
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
LACTMED
Ibandronate
Created by admin on Sat Dec 16 15:57:12 UTC 2023 , Edited by admin on Sat Dec 16 15:57:12 UTC 2023
PRIMARY
Related Record Type Details
Structure of IBANDRONIC ACID
EXCRETED UNCHANGED
The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% to 60% of the absorbed dose). Unabsorbed ibandronate is eliminated unchanged in the feces.
FARNESYL PYROPHOSPHATE SYNTHASE
TARGET -> INHIBITOR
Structure of IBANDRONATE SODIUM
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
GERANYLGERANYL PYROPHOSPHATE SYNTHASE
TARGET -> INHIBITOR
Related Record Type Details
Structure of IBANDRONIC ACID
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC DOSE

ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966